Immunosuppressants Market Report 2025

This Immunosuppressants market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The immunosuppressants market size has grown rapidly in recent years. It will grow from $25.94 billion in 2024 to $29.72 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to transplant medicine advancements, drug development and innovation, regulatory approvals, rise in transplant surgeries, clinical efficacy and safety.

The immunosuppressants market size is expected to see rapid growth in the next few years. It will grow to $48.88 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to targeted therapies and precision medicine, advancements in biologics and biosimilars, immunotherapy combinations, gene therapy and immunomodulation, drug delivery innovations. Major trends in the forecast period include expanded indications, regulatory and safety considerations, precision medicine approaches, telehealth and remote monitoring, biosimilars and generics.

The growth of the immunosuppressant market is primarily attributed to the increasing prevalence of organ transplant procedures, particularly kidney and liver transplants, driven by the rising incidences of organ failure. Notably, the American Kidney Fund reported in June 2022 that the national transplant waiting list in the US would exceed 106,000 individuals, with 87% of them awaiting kidney transplants. This surge in organ transplantation cases is expected to be a key driver for the growth of the immunosuppressant market.

The immunosuppressant market is poised for growth due to the escalating instances of autoimmune diseases. Autoimmune diseases, characterized by abnormal immune responses attacking healthy cells, tissues, and organs, are on the rise. Immunosuppressant medications prove beneficial in managing autoimmune conditions such as rheumatoid arthritis, offering relief from symptoms and slowing down disease progression. A significant example is the data from the Centers for Disease Control and Prevention in June 2023, indicating that 54.4 million adults in the US were diagnosed with arthritis, a figure expected to reach 78 million by 2040. Moreover, the United Nations' World Population Prospect data in November 2022 projected a rise in the share of the global population aged 65 and above from 10% in 2022 to 16% in 2050. This increasing prevalence of autoimmune diseases, particularly in the aging population, is anticipated to drive the demand for immunosuppressants in the market.

The emergence of Phenotypic Personalized Medicine (PPM), employing a hybrid of artificial intelligence and physician intervention, presents a novel approach. Tacrolimus, a widely used immunosuppressant for organ transplant patients, requires frequent monitoring and adjustments during hospitalization. The PPM approach utilizes a computational platform, considering factors such as the patient's historical drug response, concurrent medications, and current liver and kidney data. This approach empowers physicians to identify optimal drug and dose combinations from a range of possibilities, enhancing personalization and effectiveness in drug dosing. Artificial intelligence, through PPM, not only facilitates more personalized drug dosing but also enriches physicians' decision-making capabilities by providing clinical data rather than predicted responses.

Key players in the immunosuppressant market are focusing on developing innovative products, including oral immunosuppressive agents, to improve patient convenience and adherence to treatment. An oral immunosuppressive agent is a medication taken by mouth that reduces the immune system's activity, commonly used to prevent organ rejection in transplant patients or to manage autoimmune disorders. For example, Aurinia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Canada, received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for LUPKYNIS (voclosporin). LUPKYNIS is a novel oral immunosuppressive agent that acts as a second-generation calcineurin inhibitor. It is utilized for treating lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), in Japan. The drug works by inhibiting calcineurin, an enzyme critical for T-cell activation and proliferation, thereby helping to suppress the immune response that leads to kidney inflammation associated with lupus nephritis.

In October 2022, Amgen Inc., a U.S.-based biopharmaceutical and biotechnology company, successfully acquired ChemoCentryx Inc. for $3.7 billion. This strategic acquisition significantly augments Amgen's portfolio of drugs focused on inflammation and nephrology. Additionally, the acquisition brings three therapeutic candidates in the early stages that target chemoattractant receptors, address additional inflammatory conditions, and explore an oral cancer checkpoint. ChemoCentryx, Inc., the acquired company, is a U.S.-based biopharmaceutical firm specializing in the development and commercialization of novel drugs for cancer, autoimmune disorders, and inflammatory illnesses.

Immunosuppressants are medications used to prevent the immune system from attacking healthy cells, primarily to prevent transplant rejection and manage autoimmune diseases. Careful monitoring is necessary due to their potency and potential side effects.

Key classes of drugs in this market include corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, among others. Monoclonal antibodies are produced by cloning a single white blood cell and are traceable back to that parent cell. These medications are indicated for organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. They are distributed through hospital pharmacies, retail pharmacies, and online channels.

The immunosuppressants market research report is one of a series of new reports that provides immunosuppressants market statistics, including the immunosuppressants industry's global market size, regional shares, competitors with an immunosuppressants market share, detailed immunosuppressants market segments, market trends and opportunities, and any further data you may need to thrive in the immunosuppressants industry. This immunosuppressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the immunosuppressants market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., Mylan Laboratories Inc., Teva Pharmaceuticals USA Inc., Astellas Pharma Inc., Sandoz Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals plc, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Fresenius Kabi USA, Lupin Pharmaceuticals Inc., Strides Pharma Inc., Accord Healthcare Ltd., RPG Life Sciences Limited, Genzyme Transgenics Corp., Apotex Inc.

North America was the largest region in the immunosuppressants market in 2024. The regions covered in the immunosuppressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunosuppressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunosuppressants market consists of sales of induction drugs, maintenance drugs, corticosteroids, and calcineurin inhibitors. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.